erlotinib hydrochloride has been researched along with canertinib in 14 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 124 | 9 | 65 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | canertinib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0068 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0757 | |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | 0.0395 | |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | 0.324 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 2.94 | |
| Dipeptidyl peptidase 1 | Homo sapiens (human) | 2.7 | |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | 0.185 | |
| Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | 5.65 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0103 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baselga, J; Hammond, LA | 1 |
| Lorusso, PM | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J | 1 |
| Herbst, RS | 1 |
| Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S | 1 |
| Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E | 1 |
| Avizienyte, E; Garner, AP; Ward, RA | 1 |
| Hughes, DP; Richards, KN; Speleman, F; Trevino, J; Van Roy, N; Zage, PE; Zweidler-McKay, PA | 1 |
| Biordi, L; Festuccia, C; Ficorella, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Piccolella, M; Tombolini, V | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
5 review(s) available for erlotinib hydrochloride and canertinib
| Article | Year |
|---|---|
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2003 |
Review of epidermal growth factor receptor biology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Morpholines; Neoplasm Proteins; Panitumumab; Quinazolines; Radiation Tolerance; Receptor, ErbB-2 | 2004 |
9 other study(ies) available for erlotinib hydrochloride and canertinib
| Article | Year |
|---|---|
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins | 2008 |
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
Topics: Animals; Cell Line; Cell Proliferation; Cell Survival; Drug Combinations; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Immunoblotting; Immunoprecipitation; Interleukin-3; Lapatinib; Mice; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |
Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Knockout; Morpholines; Neoplasm Transplantation; Neuroblastoma; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays | 2011 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Dogs; Erlotinib Hydrochloride; Indazoles; Male; Mice; Morpholines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2012 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |